Breaking News

BASi, NanoViricides in Tox-Pact

November 13, 2012

BASi to conduct studies for IND applications

NanoViricides has entered into an agreement with BASi to conduct drug development studies for IND applications to the FDA for its nanoviricides drug candidates against various viral diseases.
 
BASi will conduct cGLP and non-GLP studies that are designed to assess overall safety in animals receiving multiple doses of FluCide. Specific safety pharmacology studies will also be conducted to assess the effects of FluCide on cardiovascular, respiratory and central nervous systems. These studies are required for IND submission, as well as applications for clinical trials in other countries such as Australia.
 
NanoViricides anticipates that it will need very large quantities of the drug candidate for these toxicology package studies and is currently performing scale-up studies to produce the necessary quantities. Financial terms of the pact were not disclosed.

Related Compliance:

  • Analytical Testing Outsourcing Trends Update

    Analytical Testing Outsourcing Trends Update

    January 26, 2017
    Spurred by many factors, global analytical testing services market is experiencing rapid growth in the range of 11% per year

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus